Stock 9939 KINTOR PHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-05-14 EDT 		5-day change 1st Jan Change
1.2 HKD +9.09% Intraday chart for Kintor Pharmaceutical Limited +9.09% -26.38%
04-22 Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint CI
04-22 Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine
PU
Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
PU
Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights
PU
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
PU
Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
AQ
Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
PU
Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematologic Malignancies in China
PU
Kintor Pharmaceutical : Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US
PU
Kintor Pharmaceutical : Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
PU
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
PR
Kintor Pharmaceutical : Pharma Announces 2022 Annual Results and Recent Business Progress
PU
Kintor Pharmaceutical : Pharma Announces Preclinical Data of GT1708F at AACR 2023
PU
Kintor Pharmaceutical : Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use
PU
Kintor Pharmaceutical : Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715
PU
Kintor Pharmaceutical : Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
PU
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China
PU
Kintor Pharmaceutical : Phase Ib Data of GT0918 for AR+ mBC Published in EJC
PU
Kintor Pharmaceutical : Pharma Roadshow Presentation
PU
Kintor Pharmaceutical : Pharma Announces 2022 Interim Results and Recent Business Highlights
PU
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9939 Stock
  4. News Kintor Pharmaceutical Limited
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW